» Articles » PMID: 33996548

Biomarkers (mRNAs and Non-Coding RNAs) for the Diagnosis and Prognosis of Colorectal Cancer - From the Body Fluid to Tissue Level

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 May 17
PMID 33996548
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, the diagnosis and treatment of colorectal cancer (CRC) have been continuously improved, but the mortality rate continues to be high, especially in advanced patients. CRC patients usually have no obvious symptoms in the early stage and are already in the advanced stage when they are diagnosed. The 5-year survival rate is only 10%. The blood markers currently used to screen for CRC, such as carcinoembryonic antigen and carbohydrate antigen 19-9, have low sensitivity and specificity, whereas other methods are invasive or too expensive. As a result, recent research has shifted to the development of minimally invasive or noninvasive biomarkers in the form of body fluid biopsies. Non-coding RNA molecules are composed of microRNAs, long non-coding RNAs, small nucleolar RNAs, and circular RNAs, which have important roles in the occurrence and development of diseases and can be utilized for the early diagnosis and prognosis of tumors. In this review, we focus on the latest findings of mRNA-ncRNA as biomarkers for the diagnosis and prognosis of CRC, from fluid to tissue level.

Citing Articles

Re-screening adherence to multi-target stool DNA test for colorectal cancer: real-world study in a large national population.

Greene M, Pew T, Dore M, Ebner D, Ozbay A, Johnson W Int J Colorectal Dis. 2025; 40(1):48.

PMID: 39992481 PMC: 11850584. DOI: 10.1007/s00384-025-04837-6.


Non-Coding RNA as a Biomarker in Lung Cancer.

Suri C, Swarnkar S, Bhaskar L, Verma H Noncoding RNA. 2024; 10(5).

PMID: 39452836 PMC: 11514784. DOI: 10.3390/ncrna10050050.


Gra-CRC-miRTar: The pre-trained nucleotide-to-graph neural networks to identify potential miRNA targets in colorectal cancer.

Yin R, Zhao H, Li L, Yang Q, Zeng M, Yang C Comput Struct Biotechnol J. 2024; 23:3020-3029.

PMID: 39171252 PMC: 11338065. DOI: 10.1016/j.csbj.2024.07.014.


mRNA-based therapeutic strategies for cancer treatment.

Taibi T, Cheon S, Perna F, Vu L Mol Ther. 2024; 32(9):2819-2834.

PMID: 38702886 PMC: 11403232. DOI: 10.1016/j.ymthe.2024.04.035.


Gra-CRC-miRTar: The pre-trained nucleotide-to-graph neural networks to identify potential miRNA targets in colorectal cancer.

Yin R, Zhao H, Li L, Yang Q, Zeng M, Yang C bioRxiv. 2024; .

PMID: 38659732 PMC: 11042274. DOI: 10.1101/2024.04.15.589599.


References
1.
Sarasqueta A, Forte G, Corver W, de Miranda N, Ruano D, van Eijk R . Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer. BMC Cancer. 2013; 13:277. PMC: 3682902. DOI: 10.1186/1471-2407-13-277. View

2.
He C, Huang C, Zhou R, Yu H . CircLMNB1 promotes colorectal cancer by regulating cell proliferation, apoptosis and epithelial-mesenchymal transition. Onco Targets Ther. 2019; 12:6349-6359. PMC: 6691939. DOI: 10.2147/OTT.S204741. View

3.
Mohammadi P, Saidijam M, Kaki A, Etemadi K, Shabab N, Yadegarazari R . A Pilot Study of CK19, CK20 and GCC mRNA in the Peripheral Blood as a Colorectal Cancer Biomarker Panel. Int J Mol Cell Med. 2016; 5(1):30-6. PMC: 4916781. View

4.
Wu Y, Lu W, Xu J, Shi Y, Zhang H, Xia D . Prognostic value of long non-coding RNA MALAT1 in cancer patients. Tumour Biol. 2015; 37(1):897-903. DOI: 10.1007/s13277-015-3870-8. View

5.
Zhang Y, Zhang X, Chen T, Xiang J, Yin Q, Xing Y . Circular intronic long noncoding RNAs. Mol Cell. 2013; 51(6):792-806. DOI: 10.1016/j.molcel.2013.08.017. View